Clinical Trial Update: A Safety Study of 212Pb-Pentixather Radioligand Therapy [EARLY_Phase 1]

View source ↗

Summary

An early-phase safety study of the radioligand therapy 212Pb-Pentixather is not yet recruiting, evaluating its use for lung carcinoid tumors, lung neuroendocrin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor of the Lung
• Lung Neuroendocrine Tumor
• Small Cell Lung Carcinoma

Drugs mentioned

• 212Pb-Pentixather (Lead-212 pentixather radioligand)

Snippet

Sponsor: Yusuf Menda | Conditions: Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung | EARLY_Phase 1 | Status: NOT_YET_RECRUITING